Skip to content

Improvement of a massage chair (BEG-100) on height growth in children with average: Human Subjects Research

Improvement of a massage chair (BEG-100) on height growth in children with average: Human Subjects Research

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0004673
Enrollment
38
Registered
2020-01-30
Start date
2020-02-05
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : Sit at BEG-100 and apply growth mode (lower body growth for 20 minutes and whole body growth for 10 minutes) for 24 weeks

Sponsors

Kyung Hee University Oriental Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Boys and girls at age 11 whose height between 145.0 cm and 155.0 cm (considering the size of massage chair) 2) Children who has agreed to this study and has written informed consent signed by their representative

Exclusion criteria

Exclusion criteria: 1) Growth retardation from endocrinopathy (growth hormone deficiency, hypothyroidism, type 1 diabetes, etc.) 2) History of intrauterine growth retardation 3) Diagnosis and under treatment of chronic or terminal diseases (hypertension, obesity, hyperlipidemia, diabetes, thyroid disease, cancer, etc.) 4) Diagnosis and under treatment of musculoskeletal diseases that are difficult to implement massage chair (congenital malformation, scoliosis, osteogenesis imperfecta, musculopathy, etc.) 5) Clinically significant disease or history of the liver, pancreas, kidney, nervous system, respiratory system, endocrine system, cardiovascular system, urinary system, hemopathy, tumor, or psychopathy, especially a history of severe heart disease or major psychopathy such as mania/hypomania, bipolar disorder, depressive disorder, anxiety disorder, suicidal tendency, schizophrenia, attention deficit hyperactivity disorder, and autism spectrum disorder 6) Treatments improving height growth such as growth hormone, hormone replacement therapy, medications, health functional foods, herbal medicines within four weeks prior to the screening assessment 7) Participation in another clinical study within four weeks prior to the screening assessment, or planning to participate in another clinical study during the intervention period 8) Planning to receive treatments improving height growth within the research period 9) Unsuitable for study participation judged by researchers for other reasons 10) Outside the normal range of the related examination

Design outcomes

Primary

MeasureTime frame
Height percentile

Secondary

MeasureTime frame
Height;Height standard deviation score;Bone age;Predicted height estimated from bone age;Ratio of seated height and standing height;Height standard deviation score for bone age;Growth rate;Weight;Body mass index

Countries

Korea, Republic of

Contacts

Public ContactSun Haeng Lee

Kyung Hee University Oriental Medical Center

civil011@empas.com+82-2-958-1719

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 18, 2026